Gout Chronic
10
2
4
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
20%
2 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (10)
Drug-Drug Interaction Study of ABP-671 in Gout Patients
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Developing A Gout Action Plan in Primary Care Setting in Singapore
Maintenance or Withdrawal of Urate Lowering Therapy According to Ultrasound Features in Gout Patients: a Randomised Controlled Trial Stop Treatment In Gout
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients
REduCing Immunogenicity to PegloticasE (RECIPE) Study
Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid